Page last updated: 2024-08-17

diethylnitrosamine and carfilzomib

diethylnitrosamine has been researched along with carfilzomib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Al-Hosaini, K; Al-Rikabi, AC; Aljoufi, MA; Mansour, MA; Nagi, MN	1

Other Studies

1 other study(ies) available for diethylnitrosamine and carfilzomib

Article	Year
Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma. Chemico-biological interactions, 2014, May-25, Volume: 215 Topics: Animals; Biomarkers, Tumor; Carcinogens; Carcinoma, Hepatocellular; Diethylnitrosamine; Endostatins; Fibroblast Growth Factor 2; Liver; Liver Neoplasms; Male; Matrix Metalloproteinase 2; Metallothionein; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A	2014

Article

Year

Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma.

Chemico-biological interactions, 2014, May-25, Volume: 215

Topics: Animals; Biomarkers, Tumor; Carcinogens; Carcinoma, Hepatocellular; Diethylnitrosamine; Endostatins; Fibroblast Growth Factor 2; Liver; Liver Neoplasms; Male; Matrix Metalloproteinase 2; Metallothionein; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A

2014